Inter-aorto-cava retroperitoneal paraganglioma. Case Report
Keywords:
retroperitoneal paraganglioma, inter aorto cavaAbstract
Introduction: paragangliomas are very rare extra-adrenal tumors originating from the autonomic nervous system. They are classified in functioning or non-functioning tumors, according to the production of catecholamines.Patient information: 40-year-old woman, with a history of severe arterial hypertension, who had been treated with three hypotensive drugs without obtaining control; she began to suffer diffuse abdominal pain that increased, associated with hyperpolymenorrhea and a periumbilical tumor of approximately 8 cm, painful and mobile. Laboratory tests were normal. Computed tomography and magnetic resonance imaging confirmed the diagnosis of an 8×5 cm retroperitoneal tumor attached to the aorta and displacing the inferior cava. It was necessary to carry out a highly complex surgical intervention. A tumor was found and the histological and immunohistochemical results confirmed the existence of a non-functioning extra-adrenal paraganglioma.
Conclusions: retroperitoneal paraganglioma is a rare tumor, as shown by statistics. The diagnosis was made, fundamentally, by imaging, histological and immunohistochemical studies. Treatment is fundamentally surgical, as was performed in this patient.
Downloads
References
1. Mondragón Sánchez A, Mondragón Sánchez R, Alvear Negrete M, Bernal Maldonado R, Mondragón Ballesteros R. Paraganglioma retroperitoneal inter-aorto-cavo. Cir Genl [Internet]. 2004 [citado 20/03/2020];26(4):325-329. https://www.medigraphic.com/pdfs/cirgen/cg-2004/cg044s.pdf
2. Faria J, Valente V, Lima P, Silva JA, Polónia J. Paraganglioma: a case of secondary hypertension. Rev Port Cardiol [Internet]. 2010 [citado 20/3/2020];29(10):1583-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/21265497/
3. Castro-Vega LJ, Letouzé E, Burnichon N, Buffet A, Disderot PH, Khalifa E, et al. Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun [Internet]. 2015 [citado 20/3/2020];6:6044. Disponible en: https://www.nature.com/articles/ncomms7044. https://doi.org/10.1038/ncomms7044
4. Madrigal Rubiales B, Vara Castrodeza A, Fresno Forcelledo M, Ablanedo Ablanedo P. Paragangliomas retroperitoneales extradrenales no secretantes. Arch Esp Urol [Internet]. 2002 [citado 20/3/2020];55(5):543-547. Disponible en: https://aeurologia.com/file.php?d=articlesf&f=d5c19f3bb60b76f09d5ff79c27813344ee3c4c68-es.pdf
5. Ayllón Terán MD, Torres Lorite M, Benítez Cantero JM, Sánchez Hidalgo JM, Díaz Iglesias C, Rufián Peña S. Causa rara de hipertensión arterial en la juventud: paraganglioma retroperitoneal con invasión vascular. Nefrología (Madr.) [Internet]. 2013 [citado 20/3/2020];33(3):435-437.Disponible en: https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0211-69952013000400027. https://dx.doi.org/10.3265/Nefrologia.pre2012.Oct.11744
6. Remacha L, Comino-Méndez I, Richter S, Contreras L, Currás-Freixes M, Pita G, et al. Targeted exome sequencing of krebs cycle genes reveals candidate cancer-predisposing mutations in pheochromocytomas and paragangliomas. Clin Cancer Res [Internet]. 2017 [citado 20/3/2020];23(20):6315–6324. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28720665/. https://doi.org/10.1158/1078-0432.ccr-16-2250
7. Yang C, Zhuang Z, Fliedner SMJ, Shankavaram U, Sun MG, Bullova P, et al. Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. J Mol Med (Berl) [Internet]. 2015 [citado 20/3/2020];93(1):93–104. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25263965/. https://doi.org/10.1007/s00109-014-1205-7
8. Eisenhofer G, Klink B, Richter S, Lenders JWM, Robledo M. Metabologenomics of phaeochromocytoma and paraganglioma: An integrated approach for personalised biochemical and genetic testing. Clin Biochem Rev [Internet]. 2017 [citado 20/3/2020];38(2):69–100. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759086/
9. Kantorovich V, Pacak K. New insights on the pathogenesis of paraganglioma and pheochromocytoma. F1000Res [Internet]. 2018 [citado 20/3/2020];7:F1000 Faculty Rev-1500. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173107/. https://dx.doi.org/10.12688/f1000research.14568.1
10. Jimenez C. Treatment for patients with malignant pheochromocytomas and paragangliomas: A perspective from the hallmarks of cancer. Front Endocrinol (Lausanne) [Internet]. 2018 [citado 20/3/2020];9:277. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985332/. https://dx.doi.org/10.3389/fendo.2018.00277
11. Toledo RA, Qin Y, Cheng ZM, Gao Q, Iwata S, Silva GM, et al. Recurrent mutations of chromatin-remodeling genes and kinase receptors in pheochromocytomas and paragangliomas. Clin Cancer Res [Internet]. 2016 [citado 20/3/2020];22(9):2301–2310. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854762/. https://dx.doi.org/10.1158/1078-0432.CCR-15-1841
12. Ben Aim L, Pigny P, Castro-Vega LJ, Buffet A, Amar L, Bertherat J, et al. Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma. J Med Genet [Internet]. 2019 [citado 20/3/2020];56(8):513-520. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30877234/. https://doi.org/10.1136/jmedgenet-2018-105714
13. Job S, Draskovic I, Burnichon N, Buffet A, Cros J, Lépine C, et al. Telomerase activation and ATRX mutations are independent risk factors for metastatic pheochromocytoma and paraganglioma. Clin Cancer Res [Internet]. 2019 [citado 20/3/2020];25(2):760–770. Disponible en: https://clincancerres.aacrjournals.org/content/25/2/760.full-text.pdf. https://doi.org/10.1158/1078-0432.CCR-18-0139
14. Lenders JWM, Eisenhofer G. Update on modern management of pheochromocytoma and paraganglioma. Endocrinol Metab (Seoul) [Internet]. 2017 [citado 20/3/2020];32(2):152-161. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503859/. https://dx.doi.org/10.3803/EnM.2017.32.2.152
Downloads
Published
How to Cite
Issue
Section
License
Authors who have publications with this journal agree to the following terms:
- Authors will retain their copyright and assign to the journal the right of first publication of their work, which will simultaneously be subject to a Creative Commons License / Attribution-Noncommercial 4.0 International (CC BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
- Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g., depositing it in an institutional repository or publishing it in a monographic volume) as long as the initial publication in this journal is indicated.
- Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).